Some of the members of the CHAPAS-3 Trial implementing team

CHAPAS-3 is an open-label three centre randomised phase II/III trial evaluating new solid, dispersible scored antiretroviral fixed dose combination (FDC) and single drugs in African children.

The specific objectives are to compare the pharmacokinetics, toxicity, acceptability, adherence, virological efficacy and cost-effectiveness of three first-line antiretroviral regimens in children 13 years or younger. This will be done in both previously untreated children and in children with undetectable viral load who have already been receiving stavudine-based regimens as first-line ART.

New to HIV research? Click here for a lay summary of the CHAPAS-3 trial.